Sprint Bioscience AB (publ)

OM:SPRINT Stock Report

Market Cap: SEK 117.0m

Sprint Bioscience Balance Sheet Health

Financial Health criteria checks 5/6

Sprint Bioscience has a total shareholder equity of SEK13.5M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK46.0M and SEK32.5M respectively.

Key information

0%

Debt to equity ratio

SEK 0

Debt

Interest coverage ration/a
CashSEK 31.72m
EquitySEK 13.48m
Total liabilitiesSEK 32.54m
Total assetsSEK 46.03m

Recent financial health updates

Recent updates

Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Jun 12
Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Feb 19
A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Nov 19
Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Financial Position Analysis

Short Term Liabilities: SPRINT's short term assets (SEK41.7M) exceed its short term liabilities (SEK32.5M).

Long Term Liabilities: SPRINT has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: SPRINT is debt free.

Reducing Debt: SPRINT had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SPRINT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SPRINT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 04:46
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sprint Bioscience AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siri LadowDanske Bank
Christian BinderRedeye
Johan UnnerusRedeye